Iran Diabetes Drugs and Devices Market Size (2024 - 2029)

Iran Diabetes Drugs and Devices Market Analysis

Iran's diabetes drugs and devices market size is estimated at USD 1 billion in the current year. The market is expected to reach 1.3 billion in five years, registering a CAGR of more than 4.3% during the forecast period.

Inadequate precautions that disrupt traditional patient relationships, drug shortages, disruptions to routine diabetes care, and the lack of infrastructure for telemedicine services increase the risk to developing countries during the COVID-19 pandemic. This presents the most significant challenge in diabetes care management. Diabetes is becoming increasingly common in Iran, as in many other countries. In addition to the difficulties posed by diabetes management in a poor country, Iran has faced new challenges over the past two years due to increased sanctions. During the COVID-19 crisis, the severity of sanctions in Iran more than tripled. Regular blood glucose monitoring, healthy diet, regular physical activity, medication, and adherence to foot care should be considered to control hyperglycemia better and prevent or at least delay complications in people with diabetes. This is an essential component of diabetes self-management. During the COVID-19 crisis, shortages and rising prices of devices such as insulin pens increased patient anxiety and hindered disease management.

One of the most common problems faced by patients is poor medication adherence. Many patients find it challenging to follow recommended treatments. Adherence rates for oral hypoglycemic agents (OHAs) range from 36% to 93% in managing type 1 and type 2 diabetes. Sulfonylureas are commonly used to treat type 2 diabetes. Patient compliance is critical to the effectiveness of oral diabetes therapy. It was crucial to highlight the current state of compliance with diabetes medications among patients with type 2 diabetes in Tehran and the cultural differences within the same Iranian community.

Based on the abovementioned period, the market under study is expected to grow during the analysis period.

Iran Diabetes Drugs and Devices Industry Segmentation

Patients with type 1 diabetes must be given insulin because their pancreas cannot process it. To control blood sugar levels, insulin must be offered several times daily, such as when eating or drinking. Many people with type 2 diabetes also need to take antidiabetic drugs. These drugs include diabetes medications and injections such as insulin. Russia's diabetes drugs and devices market is segmented by drugs (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs) and devices (management devices (insulin pumps, insulin pens, syringes, cartridges, and jet injectors) and monitoring devices (self-monitoring blood and continuous glucose monitoring)). The report offers the value (in USD) and volume (in unit) for the above segments.